Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia

Nature Communications

Volumn 7, Issue , 2016, Pages

  Gu, Zhaohui ^a   Churchman, Michelle ^a   Roberts, Kathryn ^a   Li, Yongjin ^a   Liu, Yu ^a   Harvey, Richard C ^b   McCastlain, Kelly ^a   Reshmi, Shalini C ^c   Payne Turner, Debbie ^a   Iacobucci, Ilaria ^a   Shao, Ying ^a   Chen, I Ming ^b   Valentine, Marcus ^a   Pei, Deqing ^a   Mungall, Karen L ^d   Mungall, Andrew J ^d   Ma, Yussanne ^d   Moore, Richard ^d   Marra, Marco ^d   Stonerock, Eileen ^c,e   Gastier Foster, Julie M ^c,e   Devidas, Meenakshi ^f   Dai, Yunfeng ^f   Wood, Brent ^g   Borowitz, Michael ^h   Larsen, Eric E ⁱ   Maloney, Kelly ^j   Mattano, Leonard A ^k   Angiolillo, Anne ^l   Salzer, Wanda L ^m   Burke, Michael J ⁿ   Gianni, Francesca ^o   Spinelli, Orietta ^o   Radich, Jerald P ^p   Minden, Mark D ^q   Moorman, Anthony V ^r   Patel, Bella ^s   Fielding, Adele K ^t   Rowe, Jacob M ^u   Luger, Selina M ^v   Bhatia, Ravi ^w   Aldoss, Ibrahim ^w   Forman, Stephen J ^x   Kohlschmidt, Jessica ^y,z   Mrózek, Krzysztof ^y   Marcucci, Guido ^x   Bloomfield, Clara D ^y   Stock, Wendy ^aa   Kornblau, Steven ^ab   Kantarjian, Hagop M ^ab   Konopleva, Marina ^ab   Paietta, Elisabeth ^ac   Willman, Cheryl L ^b   Loh, Mignon L ^ad,ae   Hunger, Stephen P ^af,ag   Mullighan, Charles G ^a   more..

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF WASHINGTON   (United States)

^h DEPARTMENT OF PATHOLOGY   (United States)

ⁱ Maine Children's Cancer Program Scarborough   (United States)

^j UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^k HARP Pharma Consulting   (United States)

^l CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^m U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

ⁿ MEDICAL COLLEGE OF WISCONSIN   (United States)

^o PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^p Fred Hutchinson Cancer Research Center   (United States)

^q PRINCESS MARGARET HOSPITAL   (Canada)

^r NEWCASTLE UNIVERSITY   (United Kingdom)

^s QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^t UNIVERSITY COLLEGE LONDON   (United Kingdom)

^u SHAARE ZEDEK MEDICAL CENTER   (Israel)

^v UNIVERSITY OF PENNSYLVANIA   (United States)

^w Heerskink School of Medicine   (United States)

^x Gehr Family Center for Leukemia Research   (United States)

^y OHIO STATE UNIVERSITY   (United States)

^z MAYO CLINIC   (United States)

^aa UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^ab UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^ac ALBERT EINSTEIN CANCER CENTER   (United States)

^ad UNIVERSITY OF CALIFORNIA   (United States)

^ae UNIVERSITY OF CALIFORNIA   (United States)

^af CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^ag UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; FORKHEAD BOX J2; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN U LIKE 1; HISTONE DEACETYLASE 9; MYOCYTE ENHANCER FACTOR 2; PANOBINOSTAT; PROTEIN; PROTEIN BCL9; PROTEIN CSF1R; PROTEIN DAZAP1; SYNOVIAL SARCOMA TRANSLOCATION CHROMOSOME 18; UNCLASSIFIED DRUG; VENETOCLAX; VINCRISTINE; VORINOSTAT; HISTONE DEACETYLASE INHIBITOR; LUCIFERASE; MEF2D PROTEIN, HUMAN; ONCOPROTEIN; TRANSCRIPTOME;

ENZYME ACTIVITY; GENE EXPRESSION; GENOMICS; IMMUNE RESPONSE; INHIBITOR; PHENOTYPE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B PROGENITOR ACUTE LYMPHOBLASTIC LEUKEMIA; CHILD; CHROMOSOME REARRANGEMENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; RNA SEQUENCE; SCHOOL CHILD; TRANSCRIPTION INITIATION; YOUNG ADULT; ANIMAL; GENE EXPRESSION REGULATION; GENE REARRANGEMENT; GENETICS; GENOMICS; METABOLISM; NIH 3T3 CELL LINE; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROCEDURES; SEQUENCE ANALYSIS; TREATMENT OUTCOME;

ANIMALS; BASE SEQUENCE; GENE EXPRESSION REGULATION, LEUKEMIC; GENE REARRANGEMENT; GENOMICS; HISTONE DEACETYLASE INHIBITORS; HUMANS; LUCIFERASES; MEF2 TRANSCRIPTION FACTORS; MICE; NIH 3T3 CELLS; ONCOGENE PROTEINS, FUSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SEQUENCE ANALYSIS, RNA; TRANSCRIPTOME; TREATMENT OUTCOME;

EID: 84994404372     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13331     Document Type: Article

References (45)

1. Hunger, S. P. & Mullighan, C. G. Redefining ALL classification: toward detecting high-risk ALL and implementing precision medicine. Blood 125, 3977-3987 (2015).
2. Hunger, S. P. & Mullighan, C. G. Acute lymphoblastic leukemia in children. N. Engl. J. Med. 373, 1541-1552 (2015).
3. Roberts, K. G. et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N. Engl. J. Med. 371, 1005-1015 (2014).
4. Moorman, A. V. The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia. Blood Rev. 26, 123-135 (2012).
5. Willis, T. G. et al. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 91, 1873-1881 (1998).
6. Gu, T. L. et al. A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia. Blood 110, 323-333 (2007).
7. Roberts, K. G. et al. Outcomes of children with BCR-ABL1-like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease. J. Clin. Oncol. 32, 3012-3020 (2014).
8. Harvey, R. C. et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 116, 4874-4884 (2010).
9. Haberland, M. et al. Regulation of HDAC9 gene expression by MEF2 establishes a negative-feedback loop in the transcriptional circuitry of muscle differentiation. Mol. Cell Biol. 27, 518-525 (2007).
10. Cox, D. Regression models and life-tables. J. R. Stat. Soc. 34, 187-220 (1972).
11. Mullighan, C. G. et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature 471, 235-239 (2011).
12. Hoggard, L. R. et al. Rational design of selective small-molecule inhibitors for beta-catenin/B-cell lymphoma 9 protein-protein interactions. J. Am. Chem. Soc. 137, 12249-12260 (2015).
13. Yang, Q. & Mao, Z. Dysregulation of autophagy and Parkinson's disease: the MEF2D link. Apoptosis 15, 1410-1414 (2010).
14. Mao, Z., Bonni, A., Xia, F., Nadal-Vicens, M. & Greenberg, M. E. Neuronal activity-dependent cell survival mediated by transcription factor MEF2. Science 286, 785-790 (1999).
15. Heng, T. S. & Painter, M. W. The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol. 9, 1091-1094 (2008).
16. Herglotz, J. et al. Essential control of early B-cell development by Mef2 transcription factors. Blood 127, 572-581 (2016).
17. Silva, M. L. et al. Establishment of a new human pre-B leukemia cell line (CEMO-1) with the translocation (1;14)(q21;q32). Leukemia 10, 575-577 (1996).
18. Dyer, M. J. et al. Immunoglobulin heavy chain (IGH) locus chromosomal translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL): rare clinical curios or potent genetic drivers? Blood 115, 1490-1499 (2009).
19. Russell, L. J. et al. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia. Blood 114, 2688-2698 (2009).
20. Mullighan, C. G. et al. Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. Nat. Genet. 41, 1243-1246 (2009).
21. Iacobucci, I. et al. Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia. Cancer Cell 29, 186-200 (2016).
22. Sampietro, J. et al. Crystal structure of a b-catenin/BCL9/Tcf4 complex. Mol. Cell 24, 293-300 (2006).
23. Katoh, M. & Katoh, M. WNT signaling pathway and stem cell signaling network. Clin. Cancer Res. 13, 4042-4045 (2007).
24. Mani, M. et al. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res. 69, 7577-7586 (2009).
25. Yang, H. T., Peggie, M., Cohen, P. & Rousseau, S. DAZAP1 interacts via its RNA-recognition motifs with the C-termini of other RNA-binding proteins. Biochem. Biophys. Res. Commun. 380, 705-709 (2009).
26. Prima, V. et al. Cloning and functional characterization of MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins created by a variant t(1;19)(q23;p13.3) in acute lymphoblastic leukemia. Leukemia 19, 806-813 (2005).
27. Prima, V. & Hunger, S. P. Cooperative transformation by MEF2D/DAZAP1 and DAZAP1/MEF2D fusion proteins generated by the variant t(1;19) in acute lymphoblastic leukemia. Leukemia 21, 2470-2475 (2007).
28. Polo, S. E. et al. Regulation of DNA-end resection by hnRNPU-like proteins promotes DNA double-strand break signaling and repair. Mol. Cell 45, 505-516 (2012).
29. Tamaki, S. et al. SS18-SSX, the oncogenic fusion protein in synovial sarcoma, is a cellular context-dependent epigenetic modifier. PLoS ONE 10, e0142991 (2015).
30. Trautmann, M. et al. SS18-SSX fusion protein-induced Wnt/beta-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene 33, 5006-5016 (2014).
31. Qiang, Y. et al. Abnormal expression of Forkhead Box J2 (FOXJ2) suppresses migration and invasion in extrahepatic cholangiocarcinoma and is associated with prognosis. Int. J. Oncol. 46, 2449-2458 (2015).
32. Wang, Y. et al. Overexpression of forkhead box J2 can decrease the migration of breast cancer cells. J. Cell Biochem. 113, 2729-2737 (2012).
33. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15-21 (2013).
34. Nicorici, D. et al. Fusion Catcher-a tool for finding somatic fusion genes in paired-end RNA-sequencing data. Preprint at bioRxiv http://dx.doi.org/10.1101/011650 (2014).
35. Edgren, H. et al. Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol. 12, R6 (2011).
36. Anders, S., Pyl, P. T. & Huber, W. HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166-169 (2015).
37. Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106 (2010).
38. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005).
39. Huang da, W., Sherman, B. T. & Lempicki, R. A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57 (2009).
40. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
41. Roberts, K. G. et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell 22, 153-166 (2012).
42. Mullighan, C. G. et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N. Engl J. Med. 360, 470-480 (2009).
43. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50, 163-170 (1966).
44. Fine, J. P. & Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496-509 (1999).
45. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. https://www.R-project.org/ (2016).